Highlights GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:11 2025-05-15 am EDT			5-day change	1st Jan Change
1,362.50 ^GBX	+1.38%		-0.11%	+1.19%

May. 15	FTSE 100 outperforms as Europe underwhelms	AN
May. 14	PRESS DIGEST-British Business - May 15	RE

Highlights

UK Stocks-Factors to watch on May 15	May. 15	RE
PRESS DIGEST-British Business - May 15	May. 14	RE
Ex-dividend day for interim dividend	May. 14	FA
Deals of the day-Mergers and acquisitions	May. 14	RE
Sector Update: Health Care	May. 14	MT
Top Midday Stories: Qatar Orders 160 Boeing Jets for Over $200 Billion; Super Micro, DataVolt Form $20 Billion Partnership	May. 14	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	May. 14	MT
GSK Strikes up to $2 Billion Deal to Acquire Boston Pharmaceuticals' Liver Disease Drug Candidate	May. 14	MT
Deals of the day-Mergers and acquisitions	May. 14	RE
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid US-China Tariff Pause, Softer Inflation Data	May. 14	MT
GSK to Acquire Liver Disease Treatment From Boston Pharmaceuticals for up to $2 Billion	May. 14	MT
Deals of the day-Mergers and acquisitions	May. 14	RE
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update	May. 14	DJ
GSK: acquisition of experimental treatment in hepatology	May. 14	CF
GSK acquires "potential best-in-class" medicine efimosfermin	May. 14	AN
GSK to buy liver disease drug for up to $2 billion	May. 14	RE
GSK to buy liver disease drug for up to $2 billion	May. 14	RE
UK Stocks-Factors to watch on May 14	May. 14	RE
Burberry swings to loss; H&T agrees terms of takeover	May. 14	AN
GSK To Acquire efimosfermin For Up To $2 Bln	May. 14	RE
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion	May. 14	DJ
GSK to Buy Boston Pharmaceuticals' Potential Liver Medicine for Up to $2 Billion	May. 14	MT
GSK plc agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.	May. 13	CI
UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink	May. 13	RE
GSK: development of belrestotug discontinued	May. 13	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : A healthy start to 2025; guidance unchanged

April 30, 2025 at 12:28 pm EDT

GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

January 13, 2025 at 03:03 pm EST

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT